Rocket Pharmaceuticals, Inc. (RCKT): Cash & Equivalents
$77.56M
As of 2025-12-31
$224.51M
As of 2026-06-30
-18.0%
3-year compound annual growth
-23.6%
5-year compound annual growth
-0.3%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $77.56M | -52.6% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $163.63M | +192.7% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $55.90M | -60.2% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $140.52M | -39.6% | 2024-02-27, Balance as of period end |
| 2021-12-31 | $232.69M | -21.7% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $297.10M | +60.3% | 2022-02-28, Balance as of period end |
| 2019-12-31 | $185.38M | +66.5% | 2021-03-01, Balance as of period end |
| 2018-12-31 | $111.36M | +513.8% | 2020-03-06, Balance as of period end |
| 2017-12-31 | $18.14M | -39.1% | 2019-03-08, Balance as of period end |
| 2016-12-31 | $29.80M | -62.8% | 2018-03-07, Balance as of period end |
| 2015-12-31 | $80.04M | n/m | 2017-03-16, Balance as of period end |
| 2014-12-31 | $3.62M | n/a | 2016-03-23, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Rocket Pharmaceuticals, Inc. (RCKT) | 2025-12-31 | $77.56M | -52.6% |
| Abbott Laboratories (ABT) | 2025-12-31 | $8.52B | +11.9% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $10.21B | -1.3% |
| TherapeuticsMD, Inc. (TXMD) | 2024-12-31 | $5.06M | +16.9% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $7.27B | +122.4% |
| Pfizer Inc (PFE) | 2025-12-31 | $1.14B | +9.5% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $19.71B | -18.2% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $93.89M | +10.9% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $14.56B | +10.0% |
Compare RCKT, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗